|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Boussios S, Seraj E, Zarkavelis G,
Petrakis D, Kollas A, Kafantari A, Assi A, Tatsi K, Pavlidis N and
Pentheroudakis G: Management of patients with recurrent/advanced
cervical cancer beyond first line platinum regimens: Where do we
stand? A literature review. Crit Rev Oncol Hematol. 108:164–174.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Liu YZ, Wu K, Huang J, Liu Y, Wang X, Meng
ZJ, Yuan SX, Wang DX, Luo JY, Zuo GW, et al: The PTEN/PI3K/Akt and
Wnt/β-catenin signaling pathways are involved in the inhibitory
effect of resveratrol on human colon cancer cell proliferation. Int
J Oncol. 45:104–112. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kim J, Eltoum IE, Roh M, Wang J and
Abdulkadir SA: Interactions between cells with distinct mutations
in c-MYC and Pten in prostate cancer. PLoS Genet.
5(e1000542)2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yanagawa N, Leduc C, Kohler D, Saieg MA,
John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA and
Tsao MS: Loss of phosphatase and tensin homolog protein expression
is an independent poor prognostic marker in lung adenocarcinoma. J
Thorac Oncol. 7:1513–1521. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Tashiro H, Blazes MS, Wu R, Cho KR, Bose
S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are
frequent in endometrial carcinoma but rare in other common
gynecological malignancies. Cancer Res. 57:3935–3940.
1997.PubMed/NCBI
|
|
8
|
Lu D, Qian J, Yin X, Xiao Q, Wang C and
Zeng Y: Expression of PTEN and survivin in cervical cancer:
Promising biological markers for early diagnosis and prognostic
evaluation. Br J Biomed Sci. 69:143–146. 2012.PubMed/NCBI
|
|
9
|
Lee JS, Choi YD, Lee JH, Nam JH, Choi C,
Lee MC, Park CS, Kim HS and Min KW: Expression of PTEN in the
progression of cervical neoplasia and its relation to tumor
behavior and angiogenesis in invasive squamous cell carcinoma. J
Surg Oncol. 93:233–240. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Yndestad S, Austreid E, Knappskog S,
Chrisanthar R, Lilleng PK, Lønning PE and Eikesdal HP: High PTEN
gene expression is a negative prognostic marker in human primary
breast cancers with preserved p53 function. Breast Cancer Res
Treat. 163:177–190. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nakanishi A, Kitagishi Y, Ogura Y and
Matsuda S: The tumor suppressor PTEN interacts with p53 in
hereditary cancer (Review). Int J Oncol. 44:1813–1819.
2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Blanco-Aparicio C, Renner O, Leal JF and
Carnero A: PTEN, more than the AKT pathway. Carcinogenesis.
28:1379–1386. 2007.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chen Z, Trotman LC, Shaffer D, Lin HK,
Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al:
Crucial role of p53-dependent cellular senescence in suppression of
Pten-deficient tumorigenesis. Nature. 436:725–730. 2005.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Alimonti A, Nardella C, Chen Z, Clohessy
JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G,
et al: A novel type of cellular senescence that can be enhanced in
mouse models and human tumor xenografts to suppress prostate
tumorigenesis. J Clin Invest. 120:681–693. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Samarakoon R, Helo S, Dobberfuhl AD,
Khakoo NS, Falke L, Overstreet JM, Goldschmeding R and Higgins PJ:
Loss of tumour suppressor PTEN expression in renal injury initiates
SMAD3- and p53-dependent fibrotic responses. J Pathol. 236:421–432.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gupta A and Dey CS: PTEN and SHIP2
regulates PI3K/Akt pathway through focal adhesion kinase. Mol Cell
Endocrinol. 309:55–62. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mise-Omata S, Obata Y, Iwase S, Mise N and
Doi TS: Transient strong reduction of PTEN expression by specific
RNAi induces loss of adhesion of the cells. Biochem Biophys Res
Commun. 328:1034–1042. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Scacheri PC, Rozenblatt-Rosen O, Caplen
NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS,
Bhattacharjee A, Meyerson M and Collins FS: Short interfering RNAs
can induce unexpected and divergent changes in the levels of
untargeted proteins in mammalian cells. Proc Natl Acad Sci USA.
101:1892–1897. 2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li DW, Liu JP, Mao YW, Xiang H, Wang J, Ma
WY, Dong Z, Pike HM, Brown RE and Reed JC: Calcium-activated
RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and
is abrogated by alpha B-crystallin through inhibition of RAS
activation. Mol Biol Cell. 16:4437–4453. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tan BJ and Chiu GN: Role of oxidative
stress, endoplasmic reticulum stress and ERK activation in
triptolide-induced apoptosis. Int J Oncol. 42:1605–1612.
2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
D'Amours D, Sallmann FR, Dixit VM and
Poirier GG: Gain-of-function of poly(ADP-ribose) polymerase-1 upon
cleavage by apoptotic proteases: Implications for apoptosis. J Cell
Sci. 114:3771–3778. 2001.PubMed/NCBI
|
|
22
|
Stein GH, Drullinger LF, Soulard A and
Dulić V: Differential roles for cyclin-dependent kinase inhibitors
p21 and p16 in the mechanisms of senescence and differentiation in
human fibroblasts. Mol Cell Biol. 19:2109–2117. 1999.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Althubiti M, Lezina L, Carrera S,
Jukes-Jones R, Giblett SM, Antonov A, Barlev N, Saldanha GS,
Pritchard CA, Cain K and Macip S: Characterization of novel markers
of senescence and their prognostic potential in cancer. Cell Death
Dis. 5(e1528)2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kim JS, Lee C, Bonifant CL, Ressom H and
Waldman T: Activation of p53-dependent growth suppression in human
cells by mutations in PTEN or PIK3CA. Mol Cell Biol. 27:662–677.
2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhou BB and Elledge SJ: The DNA damage
response: Putting checkpoints in perspective. Nature. 408:433–439.
2000.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Ming M and He YY: PTEN in DNA damage
repair. Cancer Lett. 319:125–129. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Su TH, Chang JG, Perng LI, Chang CP, Wei
HJ, Wang NM and Tsai CH: Mutation analysis of the putative tumor
suppressor gene PTEN/MMAC1 in cervical cancer. Gynecol Oncol.
76:193–199. 2000.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tornesello ML, Buonaguro L and Buonaguro
FM: Mutations of the TP53 gene in adenocarcinoma and squamous cell
carcinoma of the cervix: A systematic review. Gynecol Oncol.
128:442–448. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Qi Q, Ling Y, Zhu M, Zhou L, Wan M, Bao Y
and Liu Y: Promoter region methylation and loss of protein
expression of PTEN and significance in cervical cancer. Biomed Rep.
2:653–658. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Yaginuma Y and Westphal H: Analysis of the
p53 gene in human uterine carcinoma cell lines. Cancer Res.
51:6506–6509. 1991.PubMed/NCBI
|
|
31
|
Meric-Bernstam F, Akcakanat A, Chen H, Do
KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K,
Dong M, et al: PIK3CA/PTEN mutations and Akt activation as markers
of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res.
18:1777–1789. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150.
2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Xu X, Wagner KU, Larson D, Weaver Z, Li C,
Ried T, Hennighausen L, Wynshaw-Boris A and Deng CX: Conditional
mutation of Brca1 in mammary epithelial cells results in blunted
ductal morphogenesis and tumour formation. Nat Genet. 22:37–43.
1999.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Jonkers J, Meuwissen R, van der Gulden H,
Peterse H, van der Valk M and Berns A: Synergistic tumor suppressor
activity of BRCA2 and p53 in a conditional mouse model for breast
cancer. Nat Genet. 29:418–425. 2001.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Augello G, Puleio R, Emma MR, Cusimano A,
Loria GR, McCubrey JA, Montalto G and Cervello M: A PTEN inhibitor
displays preclinical activity against hepatocarcinoma cells. Cell
Cycle. 15:573–583. 2016.PubMed/NCBI View Article : Google Scholar
|
